Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923284 · ClinicalTrials.gov registry record
NANOTECH RCC Biomarkers
A clinical trial of Renal Cell Carcinoma and Renal Cell Cancer, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 407
- Enrollment target
- 1
- Study location
NCT02923284 is a study of Renal Cell Carcinoma and Renal Cell Cancer that has completed, run by Washington University School of Medicine. The registered enrollment target is 407 participants, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02923284, a study of Renal Cell Carcinoma and Renal Cell Cancer, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 407 participants
- Enrollment target
- 1
- Study location
Study Summary
The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules \[biomarkers\] of RCC that can be used to develop a reliable low-cost screening method at the point of service. If successful, our method would provide a diagnostic test to distinguish benign kidney masses from malignant ones, eliminating the need to surgically remove a kidney with a benign tumor.
Conditions Studied
Study Locations (1)
Missouri
- Washington University St Louis School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-01-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923284
The ClinicalTrials.gov registry entry for NCT02923284 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (70% higher). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT02923284 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02923284 about?
NCT02923284 is a clinical study titled "NANOTECH RCC Biomarkers". The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules...
What is the current status of trial NCT02923284?
This trial is currently completed. The enrollment target is 407 participants. The study started on 2016-08. Estimated completion is 2020-01-02.
What conditions does trial NCT02923284 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Renal Cell Cancer.
Who is sponsoring clinical trial NCT02923284?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02923284 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.